DV
Dividend Vision

IMNN — Imunon Inc

Imunon Inc (IMNN)

Its deepest 1-year drawdown was 77.5%.

Imunon, Inc. is a clinical-stage biotechnology company developing immunotherapies and vaccines, with its lead program IMNN-001, a DNA-based immunotherapy in Phase 3 trials for advanced ovarian cancer and earlier stages for colorectal, pancreatic, and other cancers, alongside a COVID-19 booster vaccine candidate. The company does not currently distribute dividends. Imunon appeals to investors seeking exposure to early-stage biotech development rather than current income.

IMNN key facts

Asset type
Stock
Asset class
Equity
Inception date
07/24/1995
Last close
$1.65
Market cap
$7,017,537
Average volume
55800.0
Beta
1.95
Payout ratio
0.0
Forward P/E
16.7785
EPS
$-4.52